Skip to main content

Anxiety Disorders

  • Reference work entry
  • First Online:
Family Medicine

Abstract

Anxiety disorders are characterized by an excessive fear response; these disorders are extremely prevalent among the general population and have a 2:1 female predilection [1]. Functional impairment is common with these disorders and, along with depression, are among the leading causes of disability and work related absences. As such, it is postulated that the economic burden of anxiety disorders is greater than any other psychiatric disorder due to the high prevalence and cost of medical and psychiatric treatment [2]. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), defines fear as “the emotional response to real or perceived imminent threat” and anxiety as “anticipation of future threat.” Fear typically induces surges of autonomic arousal and thoughts of immediate danger and escape, whereas anxiety typically manifests as muscular tension and avoidant behaviors. If the anxiety creates maladaptive behaviors, physical manifestations, or mental symptoms then it becomes problematic. The anxiety disorders listed in the DSM-5 tend to be highly comorbid with other psychiatric conditions [1]. Anxiety disorders discussed in this chapter are the following: separation anxiety disorder, selective mutism, specific phobia, social anxiety disorder, panic disorder, agoraphobia, and general anxiety disorder. Other anxiety disorders that do not fall under the previously mentioned disorders will briefly be discussed. In addition, obsessive-compulsive, trauma- and stress-induced related disorders will be discussed due to their relevance to anxiety. Anxiety disorders covered in this chapter are presented in Table 1 with associated ages of onset.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 899.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 999.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013. p. 607–913.

    Book  Google Scholar 

  2. Garakani A, Murrough J, Iosifescu D. Advances in psychopharmacology for anxiety disorders. Focus. 2014;XII(2):152–62.

    Article  Google Scholar 

  3. Allgulander C. Morbid anxiety as a risk factor in patients with somatic diseases: a review of recent findings. Mind Brain. 2010;1:11–9.

    Google Scholar 

  4. Mohatt J, Bennett S, Walkup J. Treatment of separation, generalized, and social anxiety disorders in youths. Am J Psychiatry. 2014;171:7.

    Article  Google Scholar 

  5. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.

    Article  PubMed  Google Scholar 

  6. Angelosante AG, Ostrowski MA, Chizkov RR. Separation anxiety disorder. In: Vasa RA, Roy AK, editors. Pediatric anxiety disorders. New York: Springer Science; 2013. p. 129–42.

    Chapter  Google Scholar 

  7. Manicavasagar V, Silove D, Wagner R, Drobny J. A self-report questionnaire for measuring separation anxiety in adulthood. Compr Psychiatry. 2003;44(2):146–53.

    Article  CAS  PubMed  Google Scholar 

  8. Lebowitz ER, Woolston J, Bar-Haim Y, et al. Family accommodation in pediatric anxiety disorders. Depress Anxiety. 2013;30(1):47–54.

    Article  PubMed  Google Scholar 

  9. Wong P. Selective mutism: a review of etiology, comorbidities, and treatment. Psychiatry. 2010;7(3):23–31.

    PubMed  PubMed Central  Google Scholar 

  10. Bandelow B. Comparison of the DSM-5 and ICD-10: panic and other anxiety disorders. CNS Spectr. 2017;22(5):404–6.

    Article  PubMed  Google Scholar 

  11. Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002;63(Suppl 8):24–34.

    PubMed  Google Scholar 

  12. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders ofthe brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:655.

    Article  CAS  PubMed  Google Scholar 

  13. Lenze EJ. Anxiety disorders in the elderly. In: Stein DJ, Hollander E, Rothbaum BO, editors. Textbook of anxiety disorders, vol. 2. Washington, DC: American Psychiatric Publishing; 2010. p. 651.

    Google Scholar 

  14. Kessler RC, Gruber M, Hettema JM, et al. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychol Med. 2008;38(3):365–74.

    Article  CAS  PubMed  Google Scholar 

  15. Scneider F, Milrod B. Gabbard’s treatments of psychiatric disorders. 5th ed. Arlington: American Psychiatric Publishing; 2014.

    Google Scholar 

  16. Grant JE, Odlaug BA, Won KS. N-Acetylcysteine, a glutamate modulator, in the treatment of Trichotillomania. Arch Gen Psychiatry. 2009;66(7):756–63.

    Article  CAS  PubMed  Google Scholar 

  17. Koran LM, Simpson HB. Guideline watch: practice guidelines for the treatment of patients with obsessive-compulsive disorder. APA Pract Guidel. 2013; 1–22.

    Google Scholar 

  18. Seim AR, Jozefiak T, Wichstrøm L, Kayed NS. Validity of reactive attachment disorder and disinhibited social engagement disorder in adolescence. Eur Child Adolesc Psychiatry. 2019;12:1–2.

    Google Scholar 

  19. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–5.

    Article  CAS  PubMed  Google Scholar 

  20. Koerner N, Antony M, Dugas M. Limitations of the Hamilton Anxiety Rating Scale as a primary outcome measure in randomized, controlled trials of treatments for generalized anxiety disorder. Am J Psychiatry. 2010;167(1):103–4.

    Article  PubMed  Google Scholar 

  21. Spitzer RL, Kroenke K, Willimas JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.

    Article  PubMed  Google Scholar 

  22. Ruiz MA, Zamorano E, García-Campayo J, et al. Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care. J Affect Disord. 2011;128(3):277–86.

    Article  PubMed  Google Scholar 

  23. Rickels K, Etemad B, Khalid-Khan S, et al. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry. 2010;67(12):1274–81.

    Article  CAS  PubMed  Google Scholar 

  24. Batterham PJ, Mackinnon AJ, Christensen H. The panic disorder screener (PADIS): development of an accurate and brief population screening tool. Psychiatry Res. 2015;228(1):72–6.

    Article  PubMed  Google Scholar 

  25. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282(18):1737–44.

    Article  CAS  PubMed  Google Scholar 

  26. Cupp M. Pharmacotherapy of anxiety disorders. Prescriber’s Lett. 2014; PL Detail-Doc #301006: 1–5.

    Google Scholar 

  27. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington: American Psychiatric Association Publishing; 2010.

    Google Scholar 

  28. Sarris J, Stough C, Bousman C. Kava in the treatment of generalized anxiety disorder: a double-blind,randomized, placebo-controlled study. J Clin Psychopharmacol. 2013;33(5):643–8.

    Article  PubMed  Google Scholar 

  29. Cuijpers P, Sijbrandij M, Koole S, Andersson G, Beekman A, Reynolds C. Adding psychotherapy toantidepressant medication in depression and anxiety disorders: a meta-analysis. Focus. 2014;XII(3):347–58.

    Article  Google Scholar 

  30. Hoepner C. OTC agents for depression, anxiety, and insomnia. Carlat Rep Psychiatr. 2013;11(7):1–3.

    Google Scholar 

  31. Bezchlibnyk-Butler K, Jeffries J, Procyshyn R, Virani A. Anxiolytic agents. In: Clinical handbook of psychotropic drugs. 20th ed. Boston: Hogrefe Publishing; 2014. p. 196–212.

    Google Scholar 

  32. Dresler T, Guhn A, Tupak SV, et al. Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder. J Neural Transm. 2013;120(1):3–29.

    Article  CAS  PubMed  Google Scholar 

  33. Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont). 2009;6(2):16.

    Google Scholar 

  34. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(Suppl 11):37–41.

    CAS  PubMed  Google Scholar 

  35. Baldwin DS, Foong T. Antidepressant drugs and sexual dysfunction. Br J Psychiatry. 2013;202:396–7.

    Article  PubMed  Google Scholar 

  36. CNS Drugs: November 1997, Volume 8, Issue 5, pp 394–401.

    Google Scholar 

  37. de Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319(7217):1106–9.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112–20.

    Article  CAS  PubMed  Google Scholar 

  39. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry. 2001;62(Suppl 18):12–7.

    CAS  PubMed  Google Scholar 

  40. Farach FJ, Pruitt LD, Jun JJ, et al. Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord. 2012;26(8):833–43.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Kim S, Roth WT, Wollburg E. Effects of therapeutic relationship, expectancy, and credibility in breathing therapies for anxiety. Bull Menn Clin. 2015;79(2):116–30.

    Article  Google Scholar 

  42. Pilkington K, Kirkwood G, Rampes H, Richardson J. Yoga for depression: the research evidence. J Affect Disord. 2005;89(1–3):13–24.

    Article  PubMed  Google Scholar 

  43. Kirkwood G, Rampes H, Tuffrey V, et al. Yoga for anxiety: a systematic review of the research evidence. Br J Sports Med. 2005;39(12):884–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Sharma M. Yoga as an alternative and complementary approach for stress management: a systematic review. J Evid Based Complementary Altern Med. 2014;19:59–67.

    Article  PubMed  Google Scholar 

  45. Biddle S. Physical activity and mental health: evidence is growing. World Psychiatry. 2016;15(2):176.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Aylett E, Small N, Bower P. Exercise in the treatment of clinical anxiety in general practice–a systematic review and meta-analysis. BMC Health Serv Res. 2018;18(1):559.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Stubbs B, Vancampfort D, Rosenbaum S, et al. An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: a meta-analysis. Psychiatry Res. 2017;249:102–8.

    Article  PubMed  Google Scholar 

  48. Bazzan A, Zabrecky G, Monti D, Newberg A. Current evidence regarding the management of mood and anxiety disorders using complementary and alternative medicine. Neurotherapeutics. 2014;14(4):411–23.

    Article  CAS  Google Scholar 

  49. Davis DM, Hayes JA. What are the benefits of mindfulness? A practice review of psychotherapy-related research. Psychotherapy. 2011;48(2):198.

    Article  PubMed  Google Scholar 

  50. Hofmann SG, Gómez AF. Mindfulness-based interventions for anxiety and depression. Psychiatr Clin. 2017;40(4):739–49.

    Google Scholar 

  51. Spijkerman MP, Pots WT, Bohlmeijer ET. Effectiveness of online mindfulness-based interventions in improving mental health: a review and meta-analysis of randomised controlled trials. Clin Psychol Rev. 2016;45:102–14.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ashley Wilk .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2022 This is a U.S. Government work and not under copyright protection in the U.S.; foreign copyright protection may apply

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Wilk, A., Garland, S.G., DeSilva, N. (2022). Anxiety Disorders. In: Paulman, P.M., Taylor, R.B., Paulman, A.A., Nasir, L.S. (eds) Family Medicine. Springer, Cham. https://doi.org/10.1007/978-3-030-54441-6_166

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54441-6_166

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54440-9

  • Online ISBN: 978-3-030-54441-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics